Adverse events and safety issues in blood donation-A comprehensive review

Blood Reviews

Volumn 26, Issue 1, 2012, Pages 33-42

  Amrein, Karin ^a   Valentin, Angelika ^a   Lanzer, Gerhard ^a   Drexler, Camilla ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adverse effects; Blood donor care; Blood donor safety; Complications; Haemovigilance; Risks

Indexed keywords

CALCIUM; CITRIC ACID; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; ETHYLENE OXIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HETASTARCH; IRON; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ANGINA PECTORIS; APHERESIS; ARTERIOVENOUS FISTULA; ARTHRALGIA; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD DONOR; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; BONE PAIN; BONE TURNOVER; BRACHIAL PLEXUS INJURY; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CAROTID ARTERY INJURY; CATARACT; CENTRAL VENOUS CATHETER; CHEST TIGHTNESS; CHILL; CLINICAL TRIAL (TOPIC); COMPARTMENT SYNDROME; CONVULSION; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; ERYTHEMA MULTIFORME; FALSE ANEURYSM; FATIGUE; FLU LIKE SYNDROME; FLUID INTAKE; GRAFT RECIPIENT; GRANULOCYTE TRANSFUSION; GROUPS BY AGE; HEART INFARCTION; HEART TAMPONADE; HEART VENTRICLE ARRHYTHMIA; HEMATOTHORAX; HOT FLUSH; HUMAN; HUNGER; HYPERCALCIURIA; HYPERTENSION; HYPERTHYROIDISM; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOVOLEMIC SHOCK; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INSOMNIA; IRON DEFICIENCY ANEMIA; IRON THERAPY; LARYNX SPASM; LEUKOCYTE TRANSFUSION; LUNG EMBOLISM; MALAISE; METABOLIC ALKALOSIS; METABOLIC BONE DISEASE; MUSCLE EXERCISE; MYALGIA; NAUSEA; NERVE INJURY; ORAL PARESTHESIA; ORAL PRURITUS; PATIENT SAFETY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMA TRANSFUSION; PNEUMOTHORAX; PRIORITY JOURNAL; PRODUCT SAFETY; PROTEIN DEPLETION; PRURITUS; PSEUDOGOUT; QT PROLONGATION; RESTLESS LEGS SYNDROME; RESTLESSNESS; SECONDARY HYPERPARATHYROIDISM; SEIZURE; SEPSIS; SIDE EFFECT; SPLEEN RUPTURE; SPLENOMEGALY; SUBARACHNOID HEMORRHAGE; SUBCLAVIAN ARTERY; SUBDURAL HEMATOMA; SWEATING; SYNCOPE; TENDON INJURY; THIRST; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; URTICARIA; VEIN PUNCTURE; WEIGHT GAIN;

ADOLESCENT; ADULT; BLOOD DONORS; BLOOD SPECIMEN COLLECTION; FEMALE; HUMANS; MALE; SAFETY; YOUNG ADULT;

EID: 83355163264     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.09.003     Document Type: Article

References (208)

1. Garozzo G., Crocco I., Giussani B., Martinucci A., Monacelli S., Randi V. Adverse reactions to blood donations: the READ project. Blood Transfus 2010, 8:49-62.
2. World Health Organization. Blood Safety - Key global fact and figures in 2011. Fact Sheet N°279 2011.
3. Winters J.L. Complications of donor apheresis. J Clin Apher 2006, 21:132-141.
4. McLeod B.C., Price T.H., Owen H., Ciavarella D., Sniecinski I., Randels M.J., et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998, 38:938-943.
5. Eder A.F., Hillyer C.D., Dy B.A., Notari E.P., Benjamin R.J. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. JAMA 2008, 299:2279-2286.
6. Reiss R.F., Harkin R., Lessig M., Mascari J. Rates of vaso-vagal reactions among first time teenaged whole blood, double red cell, and plateletpheresis donors. Ann Clin Lab Sci 2009, 39:138-143.
7. Jorgensen J., Sorensen B.S. Donor vigilance. ISBT Sci Ser 2008, 3:48-53.
8. European Directorate for the Quality of Medicine, Health Care of the Council of Europe (EDQM) Guide to the preparation, use and quality assurance of blood components. Working Group on Complications Related to Blood Donation International Society of Blood Transfusion Working Party on Haemovigilance European Haemovigilance Network 2008.
9. Taylor E.S. Procurement of blood for the armed forces: clinical lecture at Atlantic City Session. Am Med Assoc 1942, 120:119-123.
10. Greenbury C.L. An analysis of the incidence of "fainting" in 5,897 unselected blood donors. Br Med J 1942, 1:253-255.
11. Wiltbank T.B., Giordano G.F., Kamel H., Tomasulo P., Custer B. Faint and prefaint reactions in whole-blood donors: an analysis of predonation measurements and their predictive value. Transfusion 2008, 48:1799-1808.
12. Lin J.T., Ziegler D.K., Lai C.W., Bayer W. Convulsive syncope in blood donors. Ann Neurol 1982, 11:525-528.
13. Newman B.H. Blood donor complications after whole-blood donation. Curr Opin Hematol 2004, 11:339-345.
14. Kamel H., Tomasulo P., Bravo M., Wiltbank T., Cusick R., James R.C., et al. Delayed adverse reactions to blood donation. Transfusion 2010, 50:556-565.
15. Kasprisin D.O., Glynn S.H., Taylor F., Miller K.A. Moderate and severe reactions in blood donors. Transfusion 1992, 32:23-26.
16. Popovsky M.A., Whitaker B., Arnold N.L. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995, 35:734-737.
17. Trouern-Trend J.J., Cable R.G., Badon S.J., Newman B.H., Popovsky M.A. A case-controlled multicenter study of vasovagal reactions in blood donors: influence of sex, age, donation status, weight, blood pressure, and pulse. Transfusion 1999, 39:316-320.
18. Newman B.H. Vasovagal reactions in high school students: findings relative to race, risk factor synergism, female sex, and non-high school participants. Transfusion 2002, 42:1557-1560.
19. Nadler S.B. Prediction of blood volume in normal human adults. Surgery 1962, 51:224-232.
20. Newman B.H., Pichette S., Pichette D., Dzaka E. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion 2003, 43:598-603.
21. Boynton M. Complications arising in donors in a mass blood procurement project. Am J Med Sci 1945, 209:421-436.
22. Newman B.H. Donor reactions and injuries from whole blood donation. Transfus Med Rev 1997, 11:64-75.
23. Newman B.H. Arterial puncture phlebotomy in whole-blood donors. Transfusion 2001, 41:1390-1392.
24. Eder A.F., D.y B.A., Kennedy J.M., Notari Iv E.P., Strupp A., Wissel M.E., et al. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008, 48:1809-1819.
25. Newman B. Venipuncture nerve injuries after whole-blood donation. Transfusion 2001, 41:571-572.
26. Newman B., Popovsky M. Pseudoaneurysm after blood donation. Transfusion 1994, 34:935.
27. Kumar S., Agnihotri S.K., Khanna S.K. Brachial artery pseudoaneurysm following blood donation. Transfusion 1995, 35:791.
28. Lung J.A., Wilson S.D. Development of arteriovenous fistula following blood donation. Transfusion 1971, 11:145-146.
29. Omura M.C., Haimowitz M.D., Ahn S.S. Arteriovenous fistula following needle puncture for blood donation. Transfusion 2005, 45:270-273.
30. Horowitz S.H. Venipuncture-induced causalgia: anatomic relations of upper extremity superficial veins and nerves, and clinical considerations. Transfusion 2000, 40:1036-1040.
31. Newman B.H., Waxman D.A. Blood donation-related neurologic needle injury: evaluation of 2 years' worth of data from a large blood center. Transfusion 1996, 36:213-215.
32. Sorensen B.S., Johnsen S.P., Jorgensen J. Complications related to blood donation: a population-based study. Vox Sang 2008, 94:132-137.
33. Horowitz S.H. Venipuncture-induced nerve injury-a review. J Neuropathic Pain Symptom Palliation 2005, 1:109-114.
34. Simon T.L., Garry P.J., Hooper E.M. Iron stores in blood donors. JAMA 1981, 245:2038-2043.
35. Conrad M.E., Umbreit J.N., Moore E.G. Iron absorption and transport. Am J Med Sci 1999, 318:213-229.
36. Finch C.A., Cook J.D., Labbe R.F., Culala M. Effect of blood donation on iron stores as evaluated by serum ferritin. Blood 1977, 50:441-447.
37. Mast A.E., Foster T.M., Pinder H.L., Beczkiewicz C.A., Bellissimo D.B., Murphy A.T., et al. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008, 48:2197-2204.
38. Cook J.D., Flowers C.H., Skikne B.S. The quantitative assessment of body iron. Blood 2003, 101:3359-3364.
39. Cable R.G., Glynn S.A., Kiss J.E., Mast A.E., Steele W.R., Murphy E.L., et al. Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion 2011, 51:511-522.
40. Radtke H., Meyer T., Kalus U., Rocker L., Salama A., Kiesewetter H., et al. Rapid identification of iron deficiency in blood donors with red cell indexes provided by Advia 120. Transfusion 2005, 45:5-10.
41. Skikne B., Lynch S., Borek D., Cook J. Iron and blood donation. Clin Haematol 1984, 13:271-287.
42. Simon T.L. Iron, iron everywhere but not enough to donate. Transfusion 2002, 42:664.
43. Newman B.H., Satz S.L., Janowicz N.M., Siegfried B.A. Donor reactions in high-school donors: the effects of sex, weight, and collection volume. Transfusion 2006, 46:284-288.
44. Ulfberg J., Nystrom B. Restless legs syndrome in blood donors. Sleep Med 2004, 5:115-118.
45. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004, 5:385-391.
46. Birgegard G., Schneider K., Ulfberg J. High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sang 2010, 99:354-361.
47. Kazmierczak S.C., Catrou P.G. Analytical interference. More than just a laboratory problem. Am J Clin Pathol 2000, 113:9-11.
48. Dow B.C., Munro H., Frame D., Yates P. Several assays show hepatitis B positivity soon after vaccination. BMJ 1998, 316:311.
49. Zachary P., Ullmann M., Djeddi S., Meyer N., Wendling M.J., Schvoerer E., et al. Evaluation of three commercially available hepatitis C virus antibody detection assays under the conditions of a clinical virology laboratory. J Clin Virol 2005, 34:207-210. discussion 216-8.
50. European Directorate for the Quality of Medicine & HealthCare of the council of Europe (EDQM) Guide to the Preparation, use and Quality Assurance of Blood Components. Strasbourg, France 2008.
51. Ownby H.E., Korelitz J.J., Busch M.P., Williams A.E., Kleinman S.H., Gilcher R.O., et al. Loss of volunteer blood donors because of unconfirmed enzyme immunoassay screening results. Retrovirus Epidemiology Donor Study. Transfusion 1997, 37:199-205.
52. Tynell E., Norda R., Ekermo B., Sanner M., Andersson S., Bjorkman A. False-reactive microbiologic screening test results in Swedish blood donors-how big is the problem? A survey among blood centers and deferred donors. Transfusion 2007, 47:80-89.
53. Tate J., Ward G. Interferences in immunoassay. Clin Biochem Rev 2004, 25:105-120.
54. Norden A.G., Jackson R.A., Norden L.E., Griffin A.J., Barnes M.A., Little J.A. Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor. Clin Chem 1997, 43:957-962.
55. Marks V. False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. Clin Chem 2002, 48:2008-2016.
56. Hennig C., Rink L., Fagin U., Jabs W.J., Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000, 235:71-80.
57. Koike T., Sueishi M., Funaki H., Tomioka H., Yoshida S. Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984, 56:193-199.
58. Mac Kenzie W.R., Davis J.P., Peterson D.E., Hibbard A.J., Becker G., Zarvan B.S. Multiple false-positive serologic tests for HIV, HTLV-1, and hepatitis C following influenza vaccination. JAMA 1992, 268:1015-1017.
59. Wai C.T., Tambyah P.A. False-positive HIV-1 ELISA in patients with hepatitis B. Am J Med 2002, 112:737.
60. Everett D.B., Baisely K.J., McNerney R., Hambleton I., Chirwa T., Ross D.A., et al. Association of schistosomiasis with false-positive HIV test results in an African adolescent population. J Clin Microbiol 2010, 48:1570-1577.
61. Revelen R., Bordron A., Dueymes M., Youinou P., Arvieux J. False positivity in a cyto-ELISA for anti-endothelial cell antibodies caused by heterophile antibodies to bovine serum proteins. Clin Chem 2000, 46:273-278.
62. Kricka L.J. Interferences in immunoassay-still a threat. Clin Chem 2000, 46:1037-1038.
63. Willman J.H., Martins T.B., Jaskowski T.D., Hill H.R., Litwin C.M. Heterophile antibodies to bovine and caprine proteins causing false-positive human immunodeficiency virus type 1 and other enzyme-linked immunosorbent assay results. Clin Diagn Lab Immunol 1999, 6:615-616.
64. Daher R., Haidar J.H., Al-Amin H. Rifampin interference with opiate immunoassays. Clin Chem 2002, 48:203-204.
65. Ismail Y., Ismail A.A., Ismail A.A. Erroneous laboratory results: what clinicians need to know. Clin Med 2007, 7:357-361.
66. Whittaker S., Carter N., Arnold E., Shehata N., Webert K.E., Distefano L., et al. Understanding the meaning of permanent deferral for blood donors. Transfusion 2008, 48:64-72.
67. Moore M.C., Howell D.R., Barbara J.A. Donors whose blood reacts falsely positive in transfusion microbiology screening assays need not be lost to transfusion. Transfus Med 2007, 17:55-59.
68. Nilsson Sojka B., Sojka P. The blood-donation experience: perceived physical, psychological and social impact of blood donation on the donor. Vox Sang 2003, 84:120-128.
69. Roshan T.M., Rosline H., Ahmed S.A., Rapiaah M., Khattak M.N. Response rate of Malaysian blood donors with reactive screening test to transfusion medicine unit calls. Southeast Asian J Trop Med Public Health 2009, 40:1315-1321.
70. Tomasulo P.A., Anderson A.J., Paluso M.B., Gutschenritter M.A., Aster R.H. A study of criteria for blood donor deferral. Transfusion 1980, 20:511-518.
71. Shehata N., Kusano R., Hannach B., Hume H. Reaction rates in allogeneic donors. Transfus Med 2004, 14:327-333.
72. Goldman M., Fournier E., Cameron-Choi K., Steed T. Effect of changing the age criteria for blood donors. Vox Sang 2007, 92:368-372.
73. Pindyck J., Avorn J., Kuriyan M., Reed M., Iqbal M.J., Levine S.J. Blood donation by the elderly. Clinical and policy considerations. JAMA 1987, 257:1186-1188.
74. Zeiler T., Lander-Kox J., Eichler H., Alt T., Bux J. The safety of blood donation by elderly blood donors. Vox Sang 2011, 101:313-319.
75. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990, 30:583-590.
76. Apheresis: principles and practice 2003, AABB Press, Bethesda, Md.
77. Bolan C.D., Cecco S.A., Yau Y.Y., Wesley R.A., Oblitas J.M., Rehak N.N., et al. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. Transfusion 2003, 43:1414-1422.
78. Bolan C.D., Greer S.E., Cecco S.A., Oblitas J.M., Rehak N.N., Leitman S.F. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001, 41:1165-1171.
79. Das S.S., Chaudhary R., Khetan D., Shukla J.S., Agarwal P., Mishra R.B. Calcium and magnesium levels during automated plateletpheresis in normal donors. Transfus Med 2005, 15:233-236.
80. Mercan D., Bastin G., Lambermont M., Dupont E. Importance of ionized magnesium measurement for monitoring of citrate-anticoagulated plateletpheresis. Transfusion 1997, 37:418-422.
81. Bolan C.D., Wesley R.A., Yau Y.Y., Cecco S.A., Starling J., Oblitas J.M., et al. Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. Transfusion 2003, 43:1403-1413.
82. Amrein K., Katschnig C., Sipurzynski S., Stojakovic T., Lanzer G., Stach E., et al. Apheresis affects bone and mineral metabolism. Bone 2010, 46:789-795.
83. Laspina S.J., Browne M.A., McSweeney E.N., Lawlor J., Whelan D.M., Kinsella A.L., et al. QTc prolongation in apheresis platelet donors. Transfusion 2002, 42:899-903.
84. Chen Y., Bieglmayer C., Hocker P., Dettke M. Effect of acute citrate load on markers of bone metabolism in healthy volunteers. Vox Sang 2009, 97:324-329.
85. Tomita T., Takayanagi M., Kiwada K., Mieda A., Takahashi C., Hata T. Vasovagal reactions in apheresis donors. Transfusion 2002, 42:1561-1566.
86. Crocco I., Franchini M., Garozzo G., Gandini A.R., Gandini G., Bonomo P., et al. Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres. Blood Transfus 2009, 7:35-38.
87. Karger R., Kretschmer V. Maximum donation volumes per session in donor plasmapheresis. Vox Sang 2006, 91:350. author reply 351-2.
88. Karger R., Halbe M., Dinges G., Wulf H., Kretschmer V. Blood volume regulation in donors undergoing intermittent-flow plasmapheresis involving a high extracorporeal blood volume. Transfusion 2006, 46:1609-1615.
89. Karger R., Halbe M., Giffhorn-Katz S., Katz N., Kretschmer V. Atrial natriuretic peptide serum concentration decreases in donors undergoing discontinuous plasmapheresis involving a large extracorporeal blood volume. Transfusion 2007, 47:1717-1724.
90. Despotis G.J., Goodnough L.T., Dynis M., Baorto D., Spitznagel E. Adverse events in platelet apheresis donors: a multivariate analysis in a hospital-based program. Vox Sang 1999, 77:24-32.
91. Burgstaler E.A., Winters J.L., Pineda A.A. Paired comparison of Gambro Trima Accel versus Baxter Amicus single-needle plateletpheresis. Transfusion 2004, 44:1612-1620.
92. Elfath M.D., Whitley P., Jacobson M.S., Cranfill-Hupp K., Kemp D.M., McNeil D., et al. Evaluation of an automated system for the collection of packed RBCs, platelets, and plasma. Transfusion 2000, 40:1214-1222.
93. Castro E., Bueno J.L., Barea L., Gonzalez R. Hemoglobin losses due to plateletpheresis. Transfusion 1999, 39:790.
94. Koch H.M., Angerer J., Drexler H., Eckstein R., Weisbach V. Di(2-ethylhexyl)phthalate (DEHP) exposure of voluntary plasma and platelet donors. Int J Hyg Environ Health 2005, 208:489-498.
95. Buchta C., Bittner C., Höcker P., Macher M., Schmid R., Seger C., et al. Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis. Transfusion 2003, 43:1115-1120.
96. Weisbach V., Koch H.M., Angerer J., Eckstein R. Di(2-ethylhexyl)phthalate exposure of apheresis donors is procedure-related. Transfusion 2006, 46:1457-1458. author reply 1459.
97. Burdorf A., Brand T., Jaddoe V.W., Hofman A., Mackenbach J.P., Steegers E.A. The effects of work-related maternal risk factors on time to pregnancy, preterm birth and birth weight: the Generation R Study. Occup Environ Med 2011, 68:197-204.
98. Huang L.P., Lee C.C., Hsu P.C., Shih T.S. The association between semen quality in workers and the concentration of di(2-ethylhexyl) phthalate in polyvinyl chloride pellet plant air. Fertil Steril 2011, 96:90-94.
99. Muylle L., Baeten M., Avonts G., Peetermans M.E. Anaphylactoid reaction in platelet-pheresis donor with IgE antibodies to ethylene oxide. Lancet 1986, 2:1225.
100. Leitman S.F., Boltansky H., Alter H.J., Pearson F.C., Kaliner M.A. Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. N Engl J Med 1986, 315:1192-1196.
101. Kliman A., Carbone P.P., Gaydos L.A., Freireich E.J. Effects of intensive plasmapheresis on normal blood donors. Blood 1964, 23:647-656.
102. Bechtloff S., Tran-My B., Haubelt H., Stelzer G., Anders C., Hellstern P. A prospective trial on the safety of long-term intensive plasmapheresis in donors. Vox Sang 2005, 88:189-195.
103. Shanbrom E., Lundak R., Walford R.L. Long-term plasmapheresis: effects on specific plasma proteins. Transfusion 1972, 12:162-167.
104. Schulzki T., Seidel K., Storch H., Karges H., Kiessig S., Schneider S., et al. A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA). Vox Sang 2006, 91:162-173.
105. Wasi S., Santowski T., Murray S.A., Perrault R.A., Gill P. The Canadian Red Cross plasmapheresis donor safety program: changes in plasma proteins after long-term plasmapheresis. Vox Sang 1991, 60:82-87.
106. Ciszewski T.S., Ralston S., Acteson D., Wasi S., Strong S.J. Protein levels and plasmapheresis intensity. Transfus Med 1993, 3:59-65.
107. Kobayashi I., Hamaoka S., Ozawa H., Ihno M., Tamura K., Tanaka Y., et al. Hypercoagulable state induced by thrombocytapheresis. J Clin Apher 1993, 8:147-152.
108. Yilmaz M., Dikmen T., Sonmez M., Akdogan E., Durmus A., Omay S.B., et al. Change of coagulation parameters after double plateletpheresis. Transfus Apher Sci 2007, 37:161-163.
109. Rosencher J., Zuily S., Varenne O., Spaulding C., Weber S. Acute myocardial infarction secondary to platelet apheresis in a 57-year healthy donor. Int J Cardiol 2010.
110. Ovali E., Ratip S., Ozmenoglu M., Karti S.S., Ucar F., Ukinc K., et al. Large volume donor plasmapheresis in inherited thrombophilia implicated in arterial thrombosis. Transfus Apher Sci 2003, 28:201-206.
111. Kerr J.P., Liakopolou E., Brown J., Cornish J.M., Fleming D., Massey E., et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 2003, 123:114-118.
112. Oza A., Hallemeier C., Goodnough L., Khoury H., Shenoy S., Devine S., et al. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion 2006, 46:14-23.
113. Hübel K., Carter R.A., Liles W.C., Dale D.C., Price T.H., Bowden R.A., et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002, 42:1414-1421.
114. Seidel M.G., Minkov M., Witt V., Matthes-Martin S., Potschger U., Worel N., et al. Granulocyte transfusions in children and young adults: does the dose matter?. J Pediatr Hematol Oncol 2009, 31:166-172.
115. Bensinger W.I., Price T.H., Dale D.C., Appelbaum F.R., Clift R., Lilleby K., et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993, 81:1883-1888.
116. Jendiroba D.B., Lichtiger B., Anaissie E., Reddy V., O'Brien S., Kantarjian H., et al. Evaluation and comparison of three mobilization methods for the collection of granulocytes. Transfusion 1998, 38:722-728.
117. Liles W.C., Huang J.E., Llewellyn C., SenGupta D., Price T.H., Dale D.C. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997, 37:182-187.
118. Liles W.C., Rodger E., Dale D.C. Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. Transfusion 2000, 40:642-644.
119. Heuft H.G., Goudeva L., Pulver N., Grigull L., Schwella N., Blasczyk R. A dose-response analysis of lenograstim plus dexamethasone for neutrophil mobilization and collection. Transfusion 2005, 45:604-612.
120. Heuft H.G., Goudeva L., Blasczyk R. A comparative study of adverse reactions occurring after administration of glycosylated granulocyte colony stimulating factor and/or dexamethasone for mobilization of neutrophils in healthy donors. Ann Hematol 2004, 83:279-285.
121. Kikuta A., Ohto H., Nemoto K., Mochizuki K., Sano H., Ito M., et al. Therapeutic transfusions of granulocytes collected by simple bag method for children with cancer and neutropenic infections: results of a single-centre pilot study. Vox Sang 2006, 91:70-76.
122. McCullough J., Clay M., Herr G., Smith J., Stroncek D. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion 1999, 39:1136-1140.
123. Quillen K., Yau Y.Y., Leitman S.F. The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience. Transfusion 2009, 49:421-426.
124. Bux J., Cassens U., Dielschneider T., Duchscherer M., Edel E., Eichler H., et al. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang 2003, 85:322-325.
125. Ang A.L., Linn Y.C. Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era - experience from an adult haematology unit in Singapore. Transfus Med 2011, 21:13-24.
126. Leitner G., Panzer S., Reesink H.W., Stiegler G., Fischer-Nielsen A., Dickmeiss E., et al. Preparation of granulocyte concentrates by apheresis. Vox Sang 2010, 98(4):567-575.
127. Strauss R.G., Klein H.G., Leitman S.F., Price T.H., Lichtiger B., Martinez F., et al. Preparation of granulocyte concentrates by apheresis: collection modalities in the USA. Vox Sang 2011, 100:426-433.
128. Fürst C., Smiley W.K., Ansell B.M. Steroid cataract. Ann Rheum Dis 1966, 25:364-368.
129. Loredo A., Rodriguez R.S., Murillo L. Cataracts after short-term corticosteroid treatment. N Engl J Med 1972, 286:160.
130. Ghodsi Z., Strauss R.G. Cataracts in neutrophil donors stimulated with adrenal corticosteroids. Transfusion 2001, 41:1464-1468.
131. Clayton J.A., Vitale S., Kim J., Conry-Cantilena C., Byrne P., Reed G.F., et al. Prevalence of posterior subcapsular cataracts in volunteer cytapheresis donors. Transfusion 2011, 51:921-928.
132. Burch J.W., Mair D.C., Meny G.M., Moroff G., Ching S.S., Naidoff M.A., et al. The risk of posterior subcapsular cataracts in granulocyte donors. Transfusion 2005, 45:1701-1708.
133. Strauss R.G., Johnson A.T. Cataracts and corticosteroids in granulocyte donors. Transfusion 2011, 51:904-907.
134. Miflin G., Charley C., Stainer C., Anderson S., Hunter A., Russell N. Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Haematol 1996, 95:345-348.
135. Hölig K., Kramer M., Kroschinsky F., Bornhauser M., Mengling T., Schmidt A.H., et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009, 114:3757-3763.
136. Stroncek D., Shawker T., Follmann D., Leitman S.F. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003, 43:609-613.
137. Rowley S.D., Donaldson G., Lilleby K., Bensinger W.I., Appelbaum F.R. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001, 97:2541-2548.
138. Engelhardt M., Bertz H., Afting M., Waller C.F., Finke J. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol 1999, 17:2160-2172.
139. Dreger P., Suttorp M., Haferlach T., Loffler H., Schmitz N., Schroyens W. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993, 81:1404-1407.
140. Körbling M., Huh Y.O., Durett A., Mirza N., Miller P., Engel H., et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995, 86:2842-2848.
141. Yoshida I., Matsuo K., Teshima T., Hashimoto D., Tanimoto Y., Harada M., et al. Transient respiratory disturbance by granulocyte-colony-stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation. Transfusion 2006, 46:186-192.
142. Platzbecker U., Prange-Krex G., Bornhauser M., Koch R., Soucek S., Aikele P., et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001, 41:184-189.
143. Kroschinsky F., Holig K., Poppe-Thiede K., Zimmer K., Ordemann R., Blechschmidt M., et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005, 90:1665-1671.
144. Pulsipher M.A., Chitphakdithai P., Miller J.P., Logan B.R., King R.J., Rizzo J.D., et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009, 113:3604-3611.
145. Stroncek D.F., Dittmar K., Shawker T., Heatherman A., Leitman S.F. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med 2004, 2:25.
146. Nuamah N.M., Goker H., Kilic Y.A., Dagmoura H., Cakmak A. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica 2006, 91. ECR08.
147. de la Rubia J., de Arriba F., Arbona C., Pascual M.J., Zamora C., Insunza A., et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008, 93:735-740.
148. Tigue C.C., McKoy J.M., Evens A.M., Trifilio S.M., Tallman M.S., Bennett C.L. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007, 40:185-192.
149. Halter J., Kodera Y., Ispizua A.U., Greinix H.T., Schmitz N., Favre G., et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009, 94:94-101.
150. Pei R.Z., Ma J.X., Zhang P.S., Liu X.H., Cao J.J., Du X.H. Intracranial hemorrhage caused by cerebrovascular malformation after donation of rhG-CSF-primed allogeneic PBSC. Bone Marrow Transplant 2008, 42:61-62.
151. de Azevedo A.M. Goldberg Tabak D. Life-threatening capillary leak syndrome after G-CSF mobilization and collection of peripheral blood progenitor cells for allogeneic transplantation. Bone Marrow Transplant 2001, 28:311-312.
152. Arimura K., Inoue H., Kukita T., Matsushita K., Akimot M., Kawamata N., et al. Acute lung Injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica 2005, 90. ECR10.
153. Ames P.R., Rainey M.G. Consecutive pseudogout attacks after repetitive granulocyte colony-stimulating factor administration for neutropenia. Mod Rheumatol 2007, 17:445-446.
154. Kroschinsky F., Hundertmark J., Mauersberger S., Hermes M., Poppe-Thiede K., Rutt C., et al. Severe autoimmune hyperthyroidism after donation of growth factor-primed allogeneic peripheral blood progenitor cells. Haematologica 2004, 89:ECR05.
155. Minelli O., Falzetti F., Di Ianni M., Onorato M., Plebani S., Silvani C., et al. G-CSF-induced thrombocytopenia in a healthy donor. Bone Marrow Transplant 2009, 43:263-264.
156. Makita K., Ohta K., Mugitani A., Hagihara K., Ohta T., Yamane T., et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004, 33:661-665.
157. Cavallaro A.M., Lilleby K., Majolino I., Storb R., Appelbaum F.R., Rowley S.D., et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000, 25:85-89.
158. Anderlini P., Korbling M., Dale D., Gratwohl A., Schmitz N., Stroncek D., et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997, 90:903-908.
159. Mishler J.M., Hadlock D.C., Fortuny I.E., Nicora R.W., McCullough J.J. Increased efficiency of leukocyte collection by the addition of hydroxyethyl starch to the continuous flow centrifuge. Blood 1974, 44:571-581.
160. Lee J.H., Leitman S.F., Klein H.G. A controlled comparison of the efficacy of hetastarch and pentastarch in granulocyte collections by centrifugal leukapheresis. Blood 1995, 86:4662-4666.
161. Maguire L.C., Strauss R.G., Koepke J.A., Bowman R.J., Zelenski K.R., Lambert R.M., et al. The elimination of hydroxyethyl starch from the blood donors experiencing single of multiple intermittent-flow centrifugation leukapheresis. Transfusion 1981, 21:347-353.
162. Strauss R.G., Pennell B.J., Stump D.C. A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. Transfusion 2002, 42:27-36.
163. Entholzner E.K., Mielke L.L., Calatzis A.N., Feyh J., Hipp R., Hargasser S.R. Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight. Acta Anaesthesiol Scand 2000, 44:1116-1121.
164. Parker N.E., Porter J.B., Williams H.J., Leftley N. Pruritus after administration of hetastarch. Br Med J 1982, 284:385-386.
165. Sirtl C., Laubenthal H., Zumtobel V., Kraft D., Jurecka W. Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. Br J Anaesth 1999, 82:510-515.
166. Klein R.E., Mogollon G. Erythema multiforme following the infusion of hydroxyethyl starch. Transfusion 1984, 24:166-167.
167. Kreimeier U., Christ F., Kraft D., Lauterjung L., Niklas M., Peter K., et al. Anaphylaxis due to hydroxyethyl-starch-reactive antibodies. Lancet 1995, 346:49-50.
168. Bothner U., Georgieff M., Vogt N.H. Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/0.5) solution: a randomized, controlled epidemiology study. Anesth Analg 1998, 86:850-855.
169. Dieterich H.J., Kraft D., Sirtl C., Laubenthal H., Schimetta W., Polz W., et al. Hydroxyethyl starch antibodies in humans: incidence and clinical relevance. Anesth Analg 1998, 86:1123-1126.
170. Thomas E.D., Storb R. Technique for human marrow grafting. Blood 1970, 36:507-515.
171. Lannert H., Able T., Becker S., Sommer M., Braun M., Stadtherr P., et al. Optimizing BM harvesting from normal adult donors. Bone Marrow Transplant 2008, 42:443-447.
172. Gandini A., Roata C., Franchini M., Agostini E., Guizzardi E., Pontiero Giacometti P., et al. Unrelated allogeneic bone marrow donation: short- and long-term follow-up of 103 consecutive volunteer donors. Bone Marrow Transplant 2001, 28:369-374.
173. Machaczka M., Kalaitzakis E., Eleborg L., Ljungman P., Hagglund H. Comparison of general vs regional anaesthesia for BM harvesting: a retrospective study of anaesthesia-related complications. Bone Marrow Transplant 2010, 45:53-61.
174. Nishimori M., Yamada Y., Hoshi K., Akiyama Y., Hoshi Y., Morishima Y., et al. Health-related quality of life of unrelated bone marrow donors in Japan. Blood 2002, 99:1995-2001.
175. Parkkali T., Juvonen E., Volin L., Partanen J., Ruutu T. Collection of autologous blood for bone marrow donation: how useful is it?. Bone Marrow Transplant 2005, 35:1035-1039.
176. Mijovic A., Britten C., Regan F., Harrison J. Preoperative autologous blood donation for bone marrow harvests: are we wasting donors' time and blood?. Transfus Med 2006, 16:57-62.
177. Fortanier C., Kuentz M., Sutton L., Milpied N., Michalet M., Macquart-Moulin G., et al. Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: results of a randomised study. Bone Marrow Transplant 2002, 29:145-149.
178. MacLeod K.D., Whitsett S.F., Mash E.J., Pelletier W. Pediatric sibling donors of successful and unsuccessful hematopoietic stem cell transplants (HSCT): a qualitative study of their psychosocial experience. J Pediatr Psychol 2003, 28:223-230.
179. Pentz R.D., Haight A.E., Noll R.B., Barfield R., Pelletier W., Davies S., et al. The ethical justification for minor sibling bone marrow donation: a case study. Oncologist 2008, 13:148-151.
180. Wiener L.S., Steffen-Smith E., Fry T., Wayne A.S. Hematopoietic stem cell donation in children: a review of the sibling donor experience. J Psychosoc Oncol 2007, 25:45-66.
181. de Oliveira-Cardoso E.A., dos Santos M.A., Mastropietro A.P., Voltarelli J.C. Bone marrow donation from the perspective of sibling donors. Rev Lat Am Enfermagem 2010, 18:911-918.
182. World Marrow Donor Associaton (WMDA) International standards for unrelated hematopoietic stem cell donor registries 2007.
183. O'Donnell P.V., Pedersen T.L., Confer D.L., Rizzo J.D., Pulsipher M.A., Stroncek D., et al. Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood 2010, 115:5097-5101.
184. Shaw B.E. First do no harm. Blood 2010, 115:4978-4979.
185. van Walraven S.M., Nicoloso-de Faveri G., Axdorph-Nygell U.A., Douglas K.W., Jones D.A., Lee S.J., et al. Family donor care management: principles and recommendations. Bone Marrow Transplant 2010, 45:1269-1273.
186. Leitner G.C., Baumgartner K., Kalhs P., Biener D., Greinix H.T., Hoecker P., et al. Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study. Bone Marrow Transplant 2009, 43:357-363.
187. Mansfield P.F., Hohn D.C., Fornage B.D., Gregurich M.A., Ota D.M. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994, 331:1735-1738.
188. Wallace M.J., Ahrar K. Percutaneous closure of a subclavian artery injury after inadvertent catheterization. J Vasc Interv Radiol 2001, 12:1227-1230.
189. Domino K.B., Bowdle T.A., Posner K.L., Spitellie P.H., Lee L.A., Cheney F.W. Injuries and liability related to central vascular catheters: a closed claims analysis. Anesthesiology 2004, 100:1411-1418.
190. Reik R.A., Noto T.A., Fernandez H.F. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apher 1997, 12:10-13.
191. Shariatmadar S., Noto T.A. Femoral vascular access for large-volume collection of peripheral blood progenitor cells. J Clin Apher 1998, 13:99-102.
192. Sohn S.K., Kim J.G., Chae Y.S., Kim D.H., Lee N.Y., Suh J.S., et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apher 2003, 18:10-15.
193. Ditto B., France C.R. The effects of applied tension on symptoms in French-speaking blood donors: a randomized trial. Health Psychol 2006, 25:433-437.
194. Ditto B., France C.R., Albert M., Byrne N. Dismantling applied tension: mechanisms of a treatment to reduce blood donation-related symptoms. Transfusion 2007, 47:2217-2222.
195. Ditto B., France C.R., Albert M., Byrne N., Smyth-Laporte J. Effects of applied muscle tension on the likelihood of blood donor return. Transfusion 2009, 49:858-862.
196. Ando S., Kawamura N., Matsumoto M., Dan E., Takeshita A., Murakami K., et al. Simple standing test predicts and water ingestion prevents vasovagal reaction in the high-risk blood donors. Transfusion 2009, 49:1630-1636.
197. Hanson S.A., France C.R. Predonation water ingestion attenuates negative reactions to blood donation. Transfusion 2004, 44:924-928.
198. Newman B., Tommolino E., Andreozzi C., Joychan S., Pocedic J., Heringhausen J. The effect of a 473-mL (16-oz) water drink on vasovagal donor reaction rates in high-school students. Transfusion 2007, 47:1524-1533.
199. France C.R., Ditto B., Wissel M.E., France J.L., Dickert T., Rader A., et al. Predonation hydration and applied muscle tension combine to reduce presyncopal reactions to blood donation. Transfusion 2010, 50:1257-1264.
200. Røsvik A.S., Hervig T., Wentzel-Larsen T., Ulvik R.J. Effect of iron supplementation on iron status during the first week after blood donation. Vox Sang 2010, 98:e249-e256.
201. Radtke H., Tegtmeier J., Rocker L., Salama A., Kiesewetter H. Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double-blind, placebo-controlled study. Transfusion 2004, 44:1427-1432.
202. Radtke H., Mayer B., Rocker L., Salama A., Kiesewetter H. Iron supplementation and 2-unit red blood cell apheresis: a randomized, double-blind, placebo-controlled study. Transfusion 2004, 44:1463-1467.
203. Radtke H., Tegtmeier J., Rocker L., Salama A., Kiesewetter H. Compensating for iron loss in regular blood donors using ferrous gluconate and ascorbic acid. Transfusion 2005, 45:1236-1237.
204. Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. Transfusion 2006, 46:1667-1681.
205. Kishimoto M., Ohto H., Shikama Y., Kikuta A., Kimijima I., Takenoshita S. Treatment for the decline of ionized calcium levels during peripheral blood progenitor cell harvesting. Transfusion 2002, 42:1340-1347.
206. Bolan C.D., Leitman S.F. Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors. Blood 2002, 99:1878.
207. Chen Y., Hou J., Chen G., Lin H., Lin H., Chu X., et al. Calcium supplementation attenuates citrate-related changes in bone metabolism: a placebo-controlled crossover study in healthy volunteers. Bone 2011, 49(3):506-512.
208. Tran-Mi B., Storch H., Seidel K., Schulzki T., Haubelt H., Anders C., et al. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers. Vox Sang 2004, 86:189-197.